DORNASE ALPHA: THREE CLINICAL EFFECTS
Chronic diseases of lungs are characterized by the presence of mucostasis which is the reason for often aggravations of bron chopulmonary process and favors progression of the disease. The article convincingly shows the necessity of inclusion mucolytic therapy in baseline therapy in the treatment of...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Union of pediatricians of Russia
2008-03-01
|
| Series: | Педиатрическая фармакология |
| Online Access: | https://www.pedpharma.ru/jour/article/view/872 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849695667070435328 |
|---|---|
| author | O.I. Simonova |
| author_facet | O.I. Simonova |
| author_sort | O.I. Simonova |
| collection | DOAJ |
| description | Chronic diseases of lungs are characterized by the presence of mucostasis which is the reason for often aggravations of bron chopulmonary process and favors progression of the disease. The article convincingly shows the necessity of inclusion mucolytic therapy in baseline therapy in the treatment of such diseases. Detailed information is given about the ferment medication dornase alpha, its not very well known but very important non mucolitic properties, such as anti inflammatory and antibacterial. The author provides recommendations on its correct use, because performance of the rules may determine the efficiency of therapy.Key words: mucoviscidosis, chronic bron chopulmonary diseases, mucostasis, treatment, dornase alpha, children. |
| format | Article |
| id | doaj-art-e4280f85a21446d1b74e2ac1245ce11a |
| institution | DOAJ |
| issn | 1727-5776 2500-3089 |
| language | Russian |
| publishDate | 2008-03-01 |
| publisher | Union of pediatricians of Russia |
| record_format | Article |
| series | Педиатрическая фармакология |
| spelling | doaj-art-e4280f85a21446d1b74e2ac1245ce11a2025-08-20T03:19:42ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892008-03-01522632867DORNASE ALPHA: THREE CLINICAL EFFECTSO.I. Simonova0Scientific Center of Children's Health, Russian Academy of Medical Sciences, MoscowChronic diseases of lungs are characterized by the presence of mucostasis which is the reason for often aggravations of bron chopulmonary process and favors progression of the disease. The article convincingly shows the necessity of inclusion mucolytic therapy in baseline therapy in the treatment of such diseases. Detailed information is given about the ferment medication dornase alpha, its not very well known but very important non mucolitic properties, such as anti inflammatory and antibacterial. The author provides recommendations on its correct use, because performance of the rules may determine the efficiency of therapy.Key words: mucoviscidosis, chronic bron chopulmonary diseases, mucostasis, treatment, dornase alpha, children.https://www.pedpharma.ru/jour/article/view/872 |
| spellingShingle | O.I. Simonova DORNASE ALPHA: THREE CLINICAL EFFECTS Педиатрическая фармакология |
| title | DORNASE ALPHA: THREE CLINICAL EFFECTS |
| title_full | DORNASE ALPHA: THREE CLINICAL EFFECTS |
| title_fullStr | DORNASE ALPHA: THREE CLINICAL EFFECTS |
| title_full_unstemmed | DORNASE ALPHA: THREE CLINICAL EFFECTS |
| title_short | DORNASE ALPHA: THREE CLINICAL EFFECTS |
| title_sort | dornase alpha three clinical effects |
| url | https://www.pedpharma.ru/jour/article/view/872 |
| work_keys_str_mv | AT oisimonova dornasealphathreeclinicaleffects |